- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.08. | New equity right for trading, Prostatype Genomics AB | 226 | GlobeNewswire | At the request of Prostatype Genomics AB, equity rights will be traded on First North Growth Market as from 12 August 2026.
Security name:
Prostatype Genomics AB... ► Artikel lesen | |
| 04.08. | New last trading day for paid subscription shares (BTA) of Prostatype Genomics AB | 141 | GlobeNewswire | At the request of Prostatype Genomics AB, the last trading day in Prostatype Genomics AB's
paid subscription shares will be changed from
2026-08-10 to 2026-08-06.
Instrument: Paid subscription... ► Artikel lesen | |
| 27.07. | Prostatype Genomics AB: Prostatype Genomics AB announces outcome in rights issue of units | 172 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA... ► Artikel lesen | |
| 21.07. | Prostatype Genomics AB: Last day for subscription in Prostatype Genomics AB's rights issue of units is July 23, 2026 | 254 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA... ► Artikel lesen | |
| 09.07. | Prostatype Genomics AB: The subscription period in Prostatype Genomics AB's rights issue of units begins today | 261 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA... ► Artikel lesen | |
| 08.07. | Listing of units rights and paid subscription units of Prostatype Genomics AB | 263 | GlobeNewswire | With effect from July 09, 2026, the units rights in Prostatype Genomics AB will be traded on First North Growth Market. Trading will continue up until and including July 20, 2026.
... ► Artikel lesen | |
| 03.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.07.2026 | 1.089 | Xetra Newsboard | Das Instrument OCI US00089H1068 ACS A.DE C.ADR 1/5/EO-,50 EQUITY wird cum Kapitalmassnahme gehandelt am 03.07.2026 und ex Kapitalmassnahme am 06.07.2026 The instrument OCI US00089H1068 ACS A.DE C.ADR... ► Artikel lesen | |
| 22.06. | Prostatype Genomics AB: Bulletin From Annual General Meeting In Prostatype Genomics AB (publ) | 145 | GlobeNewswire (Europe) | The annual general meeting in Prostatype Genomics AB (publ), corp. reg. no 556726-0285 (the "Company") was held on 22 June 2026. Below is a summary of the resolutions adopted. All resolutions were adopted... ► Artikel lesen | |
| PROSTATYPE GENOMICS Aktie jetzt für 0€ handeln | |||||
| 25.05. | Prostatype Genomics AB: Update from Prostatype Genomics Regarding the Medicare Reimbursement Process for Prostatype in the United States | 383 | GlobeNewswire (Europe) | Prostatype Genomics has been actively engaged in the process regarding Medicare reimbursement for Prostatype® in the United States for some time. The process is currently in an intensive phase and continues... ► Artikel lesen | |
| 19.05. | Prostatype Genomics AB: Prostatype Genomics AB announces the Board of Directors' intention to resolve on a rights issue of units of approximately SEK 47.4 million | 273 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA... ► Artikel lesen | |
| 26.02. | Prostatype Genomics AB: Prostatype Genomics publishes year-end report for 2025 | 403 | GlobeNewswire (Europe) | Prostatype Genomics AB today publishes its year-end report for the full year 2025, including the interim report for the second half of 2025. The full year-end report is attached and can also be downloaded... ► Artikel lesen | |
| 11.11.25 | Prostatype Genomics AB: Previous Investments in Research and Development Unlock Hidden Assets in Prostatype Genomics | 372 | GlobeNewswire (Europe) | Alongside Prostatype Genomics (the "Company") strategic focus on the U.S. market and continued efforts to secure Medicare reimbursement, the Company has continuously invested in research and development... ► Artikel lesen | |
| 26.08.25 | Prostatype Genomics AB: Prostatype Genomics reaches important commercial breakthrough by initiating billing for Prostatype to insurance companies in the USA | 306 | GlobeNewswire (Europe) | Prostatype Genomics AB ("Prostatype Genomics" or the "Company") has reached an important commercial milestone in the USA by immediately starting to bill Prostatype® to several insurance companies. Prostatype®... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 39,810 | -0,43 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| ECKERT & ZIEGLER | 13,480 | +0,52 % | Eckert & Ziegler: Q2 review: underlying business solid, valuation attractive: Despite a slight consensus miss with Q2, ... | Eckert & Ziegler reported H1 results: adj. EBIT grew 10% yoy ex license, with the margin up 1.2pp to 22.3%, while reported adj. EBIT fell 6% yoy to € 33.3m against a base carrying € 5m of license income... ► Artikel lesen | |
| MORE LIFE COMPANY | 0,038 | 0,00 % | XFRA 20MP: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMOUNTAIN VALLEY... ► Artikel lesen | |
| CYTOSORBENTS | 0,282 | +5,22 % | Cytosorbents Corp: CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | Highlighting Four Independent Drivers of Shareholder Value
PRINCETON, N.J., Aug. 6, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the... ► Artikel lesen | |
| MEDARTIS | 99,50 | +1,02 % | Adhoc: Medartis Holding AG: Die Medartis-Gruppe beschleunigt das organische Umsatzwachstum im H1 auf 17,0 % und erzielt eine Kern-EBITDA-Marge von 18,0 % | Medartis Holding AG / Schlagwort(e): Halbjahresergebnis
Die Medartis-Gruppe beschleunigt das organische Umsatzwachstum im H1 auf 17,0 % und erzielt eine Kern-EBITDA-Marge von 18,0 % 18.08.2026... ► Artikel lesen | |
| GESUNDHEITSWELT CHIEMGAU | 10,600 | +0,95 % | EQS-Adhoc: Gesundheitswelt Chiemgau AG: Gesundheitswelt Chiemgau senkt Ergebnisprognose für das Geschäftsjahr 2026 aufgrund von einmaligen Sondereffekten von rund EUR 13,0 Mio. | EQS-Ad-hoc: Gesundheitswelt Chiemgau AG / Schlagwort(e): Prognose / Gesamtjahr
Gesundheitswelt Chiemgau AG senkt Ergebnisprognose für das Geschäftsjahr 2026 aufgrund von... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 59,53 | 0,00 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| FRESENIUS | 46,215 | -0,92 % | PRESSESPIEGEL/Unternehmen: PORSCHE, FRANKFURTER LEBEN/DWS, FRESENIUS KABI, ANTHROPIC, LEGORA | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
PORSCHE - Der Sportwagenbauer Porsche plant nach Informationen der Wirtschaftswoche... ► Artikel lesen | |
| BILLIONTOONE | 95,27 | 0,00 % | BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar | Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,890 | -0,10 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 12,970 | 0,00 % | Biotech Stocks At 52-Week Highs - PARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| HEARTFLOW | 46,760 | -0,09 % | Heartflow (HTFL) Rockets 46%: What Analysts Say and Where Hedge Funds Stand | ||
| CARL ZEISS MEDITEC | 32,140 | -0,31 % | Milliardenmarkt Augengesundheit: Warum EssilorLuxottica und Carl Zeiss Meditec auf neue Technologien setzen - und wo Rise Nano Optics ins Spiel kommt | ||
| ALIGNMENT HEALTHCARE | 12,930 | 0,00 % | Alignment Healthcare files motion to dismiss whistleblower lawsuit | ||
| BETA BIONICS | 19,490 | +0,05 % | Beta Bionics, Inc.: Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance | IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen |
Das Unternehmen PROSTATYPE GENOMICS AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+11,43 %) liegt der Kurs bei 0,008 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROSTATYPE GENOMICS AB finden Sie auf Wallstreet Online.